Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants

Johanna Svahn, Francesca Fioredda, Michaela Calvillo, Angelo C. Molinari, Concetta Micalizzi, Laura Banov, Madalina Schmidt, Daniela Caprino, Doretta Marinelli, Domenico Gallisai, Carlo Dufour

Research output: Contribution to journalArticlepeer-review


We report a case series of four infants with severe autoimmune haemolytic anaemia (AIHA) who responded to treatment with rituximab and cyclosporine after having failed first line therapy with high-dose steroid (prednisolone 4-8 mg/kg/d). Rituximab was started at 11-90 d from onset due to continued haemolysis; three infants also received cyclosporine A. Three of four infants reached complete response, defined as normal haemoglobin, reticulocytes and negative indices of haemolysis, at 7-21 months from diagnosis. In long-term follow-up two infants remained disease-free with normal immunology, one had undefined immunodeficiency and one had autoimmune lymphoproliferative syndrome.

Original languageEnglish
Pages (from-to)96-100
Number of pages5
JournalBritish Journal of Haematology
Issue number1
Publication statusPublished - Apr 2009


  • Autoimmune haemolytic anaemia
  • Cyclosporine A
  • Infants
  • Rituximab

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants'. Together they form a unique fingerprint.

Cite this